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A B S T R A C T
Purpose: Intractable epilepsy is a brain disorder characterized by recurrent seizures and intracellular
alpha-synuclein (aS) deposits; however, the neurobiological basis of this protein accumulation is still
poorly understood. This is the ﬁrst study aiming to assess whether the increase of aS concentrations in
the serum and CSF (cerebrospinal ﬂuid) could serve as a marker for aS deposition in the brain and
diagnosis of epilepsy.
Methods: This investigation enrolled 67 epileptic patients (40 with intractable epilepsy; 13 with newly
diagnosed epilepsy, and 14 with non-intractable epilepsy). CSF and serum samples were collected from
each patient and were assessed by ELISA.
Results: It was established that the concentration of aS in the CSF and serum was elevated in the epilepsy
patients, as compared to the control. However, the results of the subgroup analysis revealed that levels of
aS in the serum and CSF were increased in the intractable epileptic patients (CSF: 11.12  4.18 ng/ml;
serum: 52.93  22.11 ng/ml), whereas there was no difference in the groups with the newly diagnosed (CSF:
34.998  14.96 ng/ml; serum: 7.77  3.41 ng/ml) and non-intractable epilepsy (CSF: 8.93  4.83 ng/ml;
serum: 34.11  17.53 ng/ml).
Conclusion: Overall, we found that the rise of the aS content in the serum and CSF may facilitate the
identiﬁcation of intractable epilepsy; therefore, the determination of aS rates may serve as a valuable
prognostic marker in the clinical assessment.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Alpha-synuclein (aS) is a small, acidic synaptic protein
composed of 140 amino acid residues, normally soluble, which
is abundantly localized in the neuronal synaptic terminals of the
brain [1]. Under certain physiological conditions, aS participates in
the synaptic function. An increased intracytoplasmic aggregation
of aS is the major component of the pathologic inclusions in the
neurodegenerative diseases, including Parkinson disease [2,3],
dementia with Lewy bodies (LB) (DLB) [2], multiple systems
atrophy (MSA) [2], LB variant of Alzheimer disease (LBVAD), and
alcoholism [4]. The aS-immunostained perikaryal granules
present in the neurons of the substantia nigra and medulla, as
well as the glial cytoplasmic inclusions are within the pathologic
spectrum of aS actions and the phosphorylated aS lesions as* Corresponding author. Tel.: +86 23 89012878; fax: +86 23 68708697.
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protein is considered as a biochemical prognostic marker [3,6].
aS is abundant in the presynaptic nerve terminals within the
supragranule region of the dentate after the pilocarpine-induced
repetitive seizure occurrence [7,8]. It is mainly localized in the
neocortex, olfactory bulb, striatum, and thalamus hippocampus,
substantia nigra, thalamus, and cerebellum [9,10]. It is predomi-
nantly a neuronal protein, but can also be found in the neuroglial
cells. It affects the synaptic transmission via the regulation of
neurotransmitter release and vesicle recycling [1,11]. Mesial
temporal lobe epilepsy, the most common form of epilepsy, is
characterized by aS abnormal deposits, including neuronal cell
loss and reactive gliosis in the hippocampus [7,8].
Epilepsy is a chronic disease of the central nervous system. The
diagnosis of epilepsy is based mainly on the patient’s medical
history and the results from the electroencephalogram, but there is
a lack of an objective biomarker. Approximately one-third of the
patients are refractory to AEDs (antiepileptic drugs), and the
disease in these cases has been deﬁned as intractable epilepsy (IE)
[12,13]. For many years no reliable methods have existed toserved.
Table 1
The clinical characteristics of epilepsy groups.
Age (Y) Sex Course Drug Type
NE
60 F 1D N sGTCS
42 M 8D N GTCS
42 F 1D N sGTCS
21 F 1D N CPS, sGTCS
16 M 1M N sGTCS
58 M 3M N CPS, sGTCS
35 M 1D N CPS, GTCS
43 M 9D N sGTCS, CPS
44 F 1D N CPS
61 M 2M N GTCS
51 M 3M N sGTCS
22 M 1y N GTCS, CPS
48 F 5D N CPS
NIE
39 M 5M CBZ GTCS, CPS
39 F 1Y VPA GTCS
52 F 2Y
VPA
sGTCS
62 M 6M LEV sGTCS, CPS
32 F 5M VPA, LEV sGTCS
37 F 9M LEV CPS, SPS
26 M 2Y LEV GTCS, SPS
13 F 1y VPA CPS, GTCS
30 M 1Y LEV sGTCS, CPS
41 M 9M LEV GTCS,
17 M 1Y VPA GTCS, SPS
IE
52 M 10Y PB, CBZ, LEV,
OXZ
sGTCS, CPS
26 M 24Y CBZ, VPA, OXZ,
LTG
CPS
42 F 4Y CBZ, LEV, OXZ CPS, sGTCS
50 M 16Y VPA, LEV, CBZ sGTCS
46 M 5Y CBZ, LEV sGTCS, CPS
40 F 10Y Cbz TPM sGTCS, CPS
22 M 16Y CBZ/LTG/PB/LBZ CPS
34 F 15Y CBZ, PB sGTCS
54 M 5Y CBZ, LTG sGTCS
24 M 8Y CBZ, LTG sGTCS, SPS
54 F 40Y LTG, OXZ sGTCS, SPS
33 F 16Y LTG, PB sGTCS
31 F 8Y TPM, VPA sGTCS, CPS
66 F 6Y TPM, VPA sGTCS, CPS
45 F 10Y VPA sGTCS, CPS
26 M 17Y VPA, CBZ, LEV sGTCS
68 M 16Y TPM, VPA sGTCS, CPS
40 F 21Y VPA, LTG, OXZ CPS
60 F 2Y CBZ, LTG, OXZ sGTCS, SPS
53 F 10Y LEV, CBZ sGTCS, CPS
27 M 9Y CBZ, VPA, LEV GTCS, SPS
38 M 3Y VPA, CBZ, TPM GTCS
43 M 7Y CBZ, VPA GTCS, CPS
59 M 6Y LEV, VPA GTCS
19 F 3Y VPA, OXZ sGTCS, CPS
41 F 4Y CBZ, OXZ, LTG CPS
26 F 3Y CBZ, TPM CPS
53 M 9Y VPA, CBZ, LTG GTCS, CPS
39 M 15Y LEV, CBZ sGTCS, CPS
48 M 12Y CBZ, VPA CPS
19 F 7Y CBZ, VPA, LTTG sGTCS, CPS
41 F 20Y CBZ, PHT, PB, LTG,
LEV, TPM
sGTCS, CPS
28 M 5Y LEV, TPM, VPA sGTCS
42 F 21Y CBZ, VPA, TPM,
LTG, LEV
sGTCS
32 F 7Y OXZ, LTG, LEV GTCS, SPS
62 M 36Y CBZ, OXZ, LTG, LEV,
VPA, PHT
GTCS, SPS
28 M 6Y PB, PHT, LEV sGTCS, CPS
31 F 16Y PB, PHT, CBZ, VPA sGTCS
53 F 34Y OXZ, LTG, VPA,
LEV, PB, PHT
sGTCS, SPS
49 F 20Y PB, PHT, CBZ, VPA,
LEV, OXZ
sGTCS
Table 1 (Continued )
Age (Y) Sex Course Drug Type
32 F 5Y PB, PHT GTCS, SPS
19 F 14Y OXZ, VPA, LEV CPS
F, female; M, male; Y, year; M, month; D, day; H, hours; TPM, topamax; CBZ,
carbamazepine; PB, phenobarbital; PHT, phenytoin; LTG, lamotrigine; VPA, valproic
acid; LEV, levetiracetam; OXZ, oxcarbazepine; IE, intractable epilepsy; NIE, non-
intractable epilepsy; NE, new diagnosised epilepsy; sGTCS, secondary generalized
tonic–clonic seizures epilepsy; GTCS, generalized tonic–clonic seizures epilepsy;
CPS, complex partial seizure; SPS, simple partial seizure.
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a new clinical diagnostic biomarker would be of considerable
practical importance to the clinical identiﬁcation of the reactivity
of patients to antiepileptic medications and the drug-resistant
epilepsy [13,14].
Serum protein concentrations and CSF biomarkers have the
advantage of being safe, easy, and inexpensive to obtain [3,15]. In
our study, we determined for the ﬁrst time the concentrations of
aS in the serum and CSF of epileptic patients and examined the
changes of aS after the epileptic attack through ELISA measure-
ments.
2. Methods and materials
2.1. Subjects
Patients were recruited from the Epilepsy Clinic, the Depart-
ment of Neurology of the First Afﬁliated Hospital of Chongqing
Medical University. All patients went through a comprehensive
clinical examination, including an assessment of their medical
history, neurological and psychiatric examinations, and an
electroencephalogram performed by two professors. The cranial
magnetic resonance imaging scans found no lesions in the central
nervous system. Epilepsy was diagnosed as idiopathic and
classiﬁed according to the criteria, proposed by the International
League Against Epilepsy in 2001. The demographic data and ﬁnal
diagnoses are presented in Table 1. Samples from 67 epileptic
patients (33 men and 34 women) were collected by lumbar
puncture. The age ranged from 17 to 68 years. The epilepsy group
was divided into three subgroups, according to the criterion
applied in a previous study [16]. 13 patients of the ﬁrst one
had been diagnosed with epilepsy for the ﬁrst time (newly
diagnosed epilepsy, NE), 14 patients were seizure-free for 3
months (NIE), and 40 had at least a 2-year history of seizure
recurrence and IE.
Control samples were obtained from 22 individuals (age range
from 15 to 70) with neurosis. Physical and laboratory examination,
electrophysiologic study, brain MRI were showed the normal
results for all controls. The lumbar was performed in order to
exclude the central nervous disorders. Relevant clinical character-
istics are summarized in Table 1. This study was approved by the
human research committee of Chongqing Medical University, and
written informed consents were obtained from all participants
before the study.
2.2. Sample collection and storage
2 ml of CSF and 5 ml of venous blood samples were collected
from the subject after assigning the agreement. The blood samples
were centrifuged at 3000  g for 5 min in order to collect the serum
and then stored at 80 8C. CSF samples were centrifuged at
2000  g for 5 min and stored frozen at 80 8C until further
analysis as previously described in detail [17].
Fig. 1. The concentration of aS in serum (A) and CSF (B) in epilepsy and control. *
p > 0.05.
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The concentrations of serum-aS were measured by a commer-
cial ELISA kit (Invitrogen, catalog #KHB0061). Operation steps
were performed according to the manufacturer’s protocol. Dilution
of the serum and CSF was 1:10 and 1:1, respectively. Optical
densities were determined with a Multiskan Spectrum Microplate
Spectraphotometer microplate reader set to 450 nm (Thermo
Fisher Scientiﬁc, USA) as previous [16]. A standard curve was
constructed by plotting absorbance values versus aS concentra-
tions of calibrators.
2.4. Statistical analysis
Statistical analysis was performed by SPSS Statistics 19.0.
Descriptive data were computed using means  standard deviation
(S.D.). Differences between the epilepsy group and control group were
assessed by the independent sample t-test, and one way analysis of
variance (ANOVA) was used to compare all subgroups. Statistical
signiﬁcance was deﬁned as p < 0.05.
3. Results
In the studied epilepsy group (67 patients), 50.7% of the subjects
were women, and the average patient age was 39.84 years. The
individual clinical and demographic data of the epilepsy patients
are summarized in Table 1. A part of the patients (19.4%) suffered
from their ﬁrst epilepsy occurrence and were deﬁned as the NE
subgroup; 59.7% of the patients had a longer than 2-year history of
seizures, had been taking at least three types of AEDs regularly, and
their seizures were not controlled: they were deﬁned as the IE
subgroup; 20.8% of the patients were deﬁned as the NIE subgroup.
There were 38 secondarily generalized tonic–clonic seizures
(sGTCS), 18 generalized tonic–clonic seizures (GTCS), 35 complex
partial seizures (CPS), and 11 simple partial seizures (SPS). Table 2
represents the clinical character of these cases.
Fig. 1 shows the concentration of aS in the serum (Fig. 1A) and
CSF (Fig. 1B) and in the epilepsy and the control groups. The
concentrations of the serum aS in the epilepsy and control groups
were 52.93  22.11 ng/ml and 22.233  12.68 ng/ml, respectively,
and the difference was statistically signiﬁcant. The level of aS in the
CSF in the epileptic patients was considerably higher than that of the
control group: 11.12  4.18 ng/ml (epilepsy) versus 4.76  2.37 ng/
ml.
As seen in Fig. 2, the differences in the levels of aS in the CSF and
serum in the different therapeutic reaction subgroups were
statistically signiﬁcant (p < 0.05). The concentrations of aS in
the serum and CSF obtained from the IE subgroup wereTable 2
Clinical characteristics of epilepsy patients.
Characteristics Value
Course of epilepsy (n)
<1 year 16
1–2 years 8
>2 years 43
Seizure type (n)
Secondarily generalized tonic–clonic seizure 38
Generalized tonic–clonic seizure 18
Complex partial seizure 35
Simple partial seizure 11
Taking AEDs 54
No taking AEDs 13
History of taking AEDs (n)
Taking AEDs 54
No taking AEDs 13signiﬁcantly higher than those in the NIE, NE, and control
subgroups, whereas there was no difference in NIE, NE, and the
control (p > 0.05).
4. Discussion
The results of our study reveal the high value of establishing the
concentration of aS in CSF and serum as a candidate marker for the
diagnosis of patients with epilepsy, especially for its drug-resistant
form. The novel ﬁndings of this investigation can be summarized as
follows: First, the concentration of the total aS in the CSF and
serum should be assessed in the patients with IE. Second, the
content of aS was increased in the CSF and serum from patients
after IE, compared to the control, NE, and NIE. Third, there was no
difference between the concentrations of aS in the serum and CSF
in the patients with NE and NIE. Taken together, these results
demonstrated that aS was associated with IE, but was not related
to NIE and NE.
As already mentioned, aS is abundant in the presynaptic nerve
terminals [1] and is suggested to play a role in the synaptic
transmission via the regulation of neurotransmitter release and
vesicle recycling [1,11], in the mitochondrial and synaptic dysfunc-
tion and neuronal apoptosis [1], and in Ca2+ homeostasis [18]. The
intracytoplasmic aggregation of aS in patients can serve as a
candidate marker for the diagnosis of Parkinson’s disease, multiple
Fig. 2. The concentration of aS in CSF and serum in different subgroup. NE, newly
diagnosed epilepsy; NIE, non-intractable epilepsy; IE, intractable epilepsy. (A)
Serum concentration; (B) CSF concentration. * p < 0.05 versus NIE; ~ p < 0.05
versus NE, ~ p > 0.05 versus NE.
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[3]. The aggregated aS is believed to be involved in the pathogenesis
of a previous disease. However, the underlying mechanisms are still
unclear. Previous studies found that the elevated aS expression is
associated with epileptogenesis [7,8]. In the pilocarpine-induced
status epilepticus (SE) models, the Western blot analysis of dentate
lysates revealed that SE triggered a 12.8% increase in the aS
expression. The immunohistochemical analysis detected an upre-
gulation of aS within the supragranule region of the dentate gyrus
[8]. Identical results were obtained in the hippocampus of patients
with mesial temporal lobe epilepsy [7].
The aS concentrations in CSF are exceedingly low in both the
control and disease populations, making the assay development
challenging [3]. The measured quantity of aS is nearly same in NE
and NIE, nevertheless, found to be high in IE. This clearly
emphasize that the increment in the amount of aS might be
related with convulsive seizures activity. ELISA is more sensitive to
the detection of the presence of proteins than the two-dimensional
gel electrophoresis. Serum biomarkers have the advantage of being
safe, easy, and inexpensive to obtain [3]. Therefore, in our study,
we tested the expression of aS in the serum and CSF from epilepsy
patients and found that it was increased in the intractable epilepsy
patients. The mechanism leading to the elevated concentrations of
aS in the CSF and serum was unclear. To our knowledge, the
possible explanation of the rise of aS level was that the protein was
able to pass the blood brain barrier (BBB) after seizures.
However, there are some limits in our study. First, aS exists in a
number of different forms, including total and oligomeric aS, and its
phosphorylated forms (Ser129, Ser87), while this study was
designed for the detection of the totalaS. There were also difﬁculties
in obtaining the commercial ELISA agent. Nevertheless, our data
showed a pathway for the correction of the drug-refractory, drug-
effective, and newly diagnosed epilepsy. The conduction of future
examinations is important to test the level of the oligomeric aS andthe phosphorylation status of aS in epilepsy patients. Moreover,
since previous studies had investigated the expression of this
protein in animals and patients with epilepsy, we did not research its
further activity mechanisms. Third, we did not test this protein by
the use of a large number of samples because it is difﬁcult to obtain
CSF samples with recurrent epilepsy.
5. Conclusion
In conclusion, we revealed that the levels of aS in the serum and
CSF were increased in the IE patients. aS could be a candidate
biological marker in epilepsy and IE. However, these ﬁndings
require further conﬁrmation, and a larger number of epileptic
patients with regular follow-up would enable us to understand
better the potential role of aS in epilepsy.
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